Show simple item record

dc.contributor.authorMartin, Stephen A
dc.contributor.authorBosse, Jordon
dc.contributor.authorWilson, Amanda
dc.contributor.authorLosikoff, Phyllis
dc.contributor.authorChiodo, Lisa
dc.date2022-08-11T08:09:50.000
dc.date.accessioned2022-08-23T16:45:11Z
dc.date.available2022-08-23T16:45:11Z
dc.date.issued2018-04-25
dc.date.submitted2018-06-15
dc.identifier.citation<p>Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7. <a href="https://doi.org/10.1186/s13722-018-0111-7">Link to article on publisher's site</a></p>
dc.identifier.issn1940-0632 (Linking)
dc.identifier.doi10.1186/s13722-018-0111-7
dc.identifier.pmid29690936
dc.identifier.urihttp://hdl.handle.net/20.500.14038/40632
dc.description.abstractFor over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been foregone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We describe here both the need for and process of chronic HCV care under the roof of addiction medicine.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=29690936&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rights© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectChronic hepatitis C
dc.subjectCirrhosis
dc.subjectContinuity of care
dc.subjectHepatitis C epidemiology
dc.subjectHepatitis C treatment
dc.subjectOpioid use disorder
dc.subjectProject ECHO
dc.subjectTreatment cascade
dc.subjectClinical Epidemiology
dc.subjectCommunity Health and Preventive Medicine
dc.subjectEpidemiology
dc.subjectHealth Services Administration
dc.subjectHealth Services Research
dc.subjectSubstance Abuse and Addiction
dc.subjectVirus Diseases
dc.titleUnder one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care
dc.typeJournal Article
dc.source.journaltitleAddiction science and clinical practice
dc.source.volume13
dc.source.issue1
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=4447&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/3436
dc.identifier.contextkey12326404
refterms.dateFOA2022-08-23T16:45:11Z
html.description.abstract<p>For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been foregone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We describe here both the need for and process of chronic HCV care under the roof of addiction medicine.</p>
dc.identifier.submissionpathoapubs/3436
dc.contributor.departmentDepartment of Family Medicine and Community Health
dc.source.pages10


Files in this item

Thumbnail
Name:
s13722_018_0111_7.pdf
Size:
680.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Except where otherwise noted, this item's license is described as © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.